Recent trials comparing EGFR-inhibitors versus vascular endothelial growth factor inhibitors in combination with chemotherapy in RASwt mCRC have indicated benefit from EGFR-inhibitors in left-sided cancers but not in right-sided cancers, albeit not universally [17, 43, 46, 52]. This evidence concerns the gene VEGFA and cancer.